Literature DB >> 7632166

Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver.

H Ohara1, Y Miyabe, Y Deyashiki, K Matsuura, A Hara.   

Abstract

In this study, we compared the enzymatic reduction of 10 drugs with a ketone group by homogeneous carbonyl reductase, aldehyde reductase and three dihydrodiol dehydrogenases of human liver cytosol. At least one and in some cases all of the three dihydrodiol dehydrogenases reduced each of the ten drugs. Among these naloxone, naltrexone, befunolol, ethacrynic acid and ketoprofen were substrates specific for the dehydrogenases. The other drugs--haloperidol, metyrapone, loxoprofen, daunorubicin and acetohexamide--were highly reduced by carbonyl reductase and/or aldehyde reductase. The dihydrodiol dehydrogenases also showed lower Km values for haloperidol and loxoprofen than did carbonyl reductase. The results indicate that the three dihydrodiol dehydrogenases, as well as the two reductases, are implicated in the reduction of ketone-containing drugs in human liver cytosol.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632166     DOI: 10.1016/0006-2952(95)00124-i

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

Review 1.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

Authors:  Xing-Chen Peng; Feng-Ming Gong; Meng Wei; Xi Chen; Ye Chen; Ke Cheng; Feng Gao; Feng Xu; Feng Bi; Ji-Yan Liu
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

Review 3.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

4.  Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.

Authors:  Kaori Matsumoto; Tetsuya Hasegawa; Junichi Koyanagi; Tamiko Takahashi; Masayuki Akimoto; Kenji Sugibayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-06       Impact factor: 2.441

5.  CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Authors:  Adolfo Quiñones-Lombraña; Nasi Li; Virginia Del Solar; G Ekin Atilla-Gokcumen; Javier G Blanco
Journal:  Biopharm Drug Dispos       Date:  2018-06       Impact factor: 1.627

Review 6.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

7.  Identification of amino acid residues responsible for differences in substrate specificity and inhibitor sensitivity between two human liver dihydrodiol dehydrogenase isoenzymes by site-directed mutagenesis.

Authors:  K Matsuura; Y Deyashiki; K Sato; N Ishida; G Miwa; A Hara
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

8.  Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase.

Authors:  L S Ireland; D J Harrison; G E Neal; J D Hayes
Journal:  Biochem J       Date:  1998-05-15       Impact factor: 3.857

9.  Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal.

Authors:  Shulin Xiang; Robert T Dauchy; Adam Hauch; Lulu Mao; Lin Yuan; Melissa A Wren; Victoria P Belancio; Debasis Mondal; Tripp Frasch; David E Blask; Steven M Hill
Journal:  J Pineal Res       Date:  2015-04-20       Impact factor: 13.007

10.  AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.

Authors:  Linlin Zhong; Honglin Shen; Chenfei Huang; Hongwu Jing; Deliang Cao
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.